CRT (Cardiac resynchronisation therapy) devices to remain outside functional indication, FDA insists
This article was originally published in Clinica
Executive Summary
Cardiac resynchronisation therapy (CRT) devices cannot take advantage of the novel functional indication - and associated reduced regulatory costs - enjoyed by some implantable cardioverter defibrillators (ICDs), the US FDA says in a new guidance document.